(Multi-)organ-on-chip technologies for the development of personalized (disease) models
CompanyReact4Life, Genova, Italy
To improve cancer research and drug development, the company React4Life has specialized in the development of organ-on-chip technologies (MIVO). The MIVO platforms are compatible with various tissue samples and enable the cultivation of three-dimensional personalized models in a controlled microenvironment. The single organ platforms are used to research specific organ functions and to investigate the effects of drugs on specific organs, such as the influence of cardiac drugs on the pumping power of the heart muscle tissue. The multi-organ platforms simulate the interaction between different organs and enable research into disease- or drug-induced interactions, such as the consequences of the invasion of malignant cancer cells into other tissues. The (multi-)organ platforms offer an innovative solution for researching specific organ functions and modelling various diseases. The microfluidic models developed with MIVO are therefore suitable for a variety of different studies and can help to improve the safety assessment of drugs and accelerate the development of (personalized) drugs.
MIVO Organ-on-chip
www.react4life.com
Added on: 10-24-2023
[1] https://www.react4life.com/mivo-tecnology/
